GEN Exclusives

More »

GEN News Highlights

More »
Mar 19, 2007

AtheroGenics’ Shares Sink after a Disappointing Phase III for Atherosclerosis Drug

  • AtheroGenics’ candidate to treat atherosclerosis failed to meet its endpoint in Phase III evaluation. The company reports, however, that certain predefined endpoints were attained.

    The company’s shares fell 61% to open trading at $3.04.

    The ARISE study did not show a difference from placebo in its composite primary endpoint. However, the AtheroGenics says, there was a reduction in the composite of hard atherosclerotic clinical endpoints, composed of cardiovascular death, myocardial infarction, and stroke, as well as an improvement in several key diabetes parameters.

    After completion of the final analysis, AstraZeneca, who is collaborating with AtheroGenics on this compound, has 45 days to decide whether or not to continue with the collaboration.

    The Phase III, double-blind, placebo-controlled trial was conducted in over 6,100 patients with a recent acute coronary syndrome. The trial was conducted in 259 cardiac centers in the U.S., U.K., Canada, and South Africa.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?